This started as an anecdote — people on GLP-1 drugs saying they’d lost interest in alcohol. It is now a randomised controlled trial with a better number needed to treat than any medication currently approved for the condition.
The evidence has moved twice. First, a JAMA Psychiatry trial published in 2025 randomised 48 non-treatment-seeking adults with alcohol use disorder to low-dose semaglutide or placebo over nine weeks. It reduced craving, drinks per drinking day and heavy drinking days, and cut consumption in a laboratory self-administration task measured by grams of alcohol and breath alcohol concentration.
Then a much stronger trial. Published in The Lancet in 2026, a 26-week double-blind trial randomised 108 treatment-seeking patients with moderate-to-severe alcohol use disorder and comorbid obesity to semaglutide 2.4 mg weekly or placebo — on top of standard cognitive behavioural therapy. It hit its primary endpoint: a significant reduction in heavy drinking days. The reported number needed to treat was 4.3, against 7 or higher for medications already approved for alcohol use disorder. 🍷
- The 2025 trial
- The 2026 Lancet trial
- What “number needed to treat 4.3” means
- The detail everyone skips: it was added to therapy
- The comorbid obesity question
- What these trials don’t establish
- It is not approved for this
- The treatments that already exist
- The warning that matters most
- How to raise this with a doctor
- Thiamine and heavy drinking
- Frequently asked questions
- Your checklist
The 2025 trial
The first proper randomised test of this observation was published in JAMA Psychiatry in 2025.
| Element | Detail |
|---|---|
| Participants | 48 adults with alcohol use disorder |
| Important qualifier | Non-treatment-seeking |
| Dosing | 0.25 mg/week × 4 weeks, 0.5 mg/week × 4 weeks, 1.0 mg × 1 week |
| Comparator | Placebo, weekly clinic visits |
| Findings | Reduced craving, drinks per drinking day, heavy drinking days |
| Laboratory measure | Lower grams of alcohol consumed and lower breath alcohol concentration |
Two features made it interesting beyond its size. The doses were low — well below what’s used for weight management — suggesting the effect isn’t simply a by-product of appetite suppression at high doses. And the laboratory self-administration task is an objective measure: participants were given the opportunity to drink and the researchers measured how much they actually consumed, rather than relying on self-report.
The honest limitation: 48 people is small, and “non-treatment-seeking” means these were people not actively trying to cut down — which cuts both ways. It removes the motivation confound, but it also isn’t the population a doctor would be prescribing to.
The 2026 Lancet trial
This is the study that changed the picture, and it addressed most of the first trial’s weaknesses.
| Element | Detail |
|---|---|
| Published | The Lancet, 2026 |
| Design | 26-week, single-centre, randomised, double-blind, placebo-controlled |
| Participants | 108 treatment-seeking patients |
| Population | Moderate-to-severe alcohol use disorder and comorbid obesity |
| Intervention | Semaglutide 2.4 mg weekly subcutaneously |
| Comparator | Saline placebo |
| Both arms also received | Standard cognitive behavioural therapy |
| Primary endpoint | Reduction in heavy drinking days at 26 weeks (ANCOVA) |
| Result | Significant reduction vs placebo |
| Also reduced | Total consumption, drinks per drinking day, self-reported craving |
| Number needed to treat | 4.3 |
Everything about this is a step up: treatment-seeking patients rather than volunteers, 26 weeks rather than nine, the full 2.4 mg dose, and a pre-specified primary endpoint that it hit.
What “number needed to treat 4.3” means
This is the figure worth understanding properly, because it’s the most impressive number in the whole story and it’s easy to misread.
Number needed to treat is how many people must receive a treatment for one additional person to benefit. Lower is better. An NNT of 4.3 means roughly one in every four to five people treated gets a benefit they would not have had on placebo.
The comparison given is the striking part: 4.3 against 7 or higher for medications already approved for alcohol use disorder.
First, NNTs from different trials aren’t directly comparable — they depend on the population, the definition of “benefit,” and the trial length. A cross-trial comparison is suggestive, not decisive.
Second, this NNT comes from 108 patients at a single centre. Effect sizes from single small trials frequently shrink when larger, multi-centre trials follow. That’s not a criticism of the study — it’s how the evidence base normally matures. Treat 4.3 as a genuinely encouraging early estimate rather than a settled figure.
The detail everyone skips: it was added to therapy
This is the single most-omitted fact in coverage of the Lancet trial, and it changes what the result means.
Both arms received standard cognitive behavioural therapy. The semaglutide group got the drug in addition to CBT; the placebo group got saline in addition to CBT.
So the finding is not “semaglutide treats alcohol use disorder.” It is: “semaglutide added to structured psychological treatment produced better results than psychological treatment alone.”
That’s still a good result — it’s how most successful additions to psychiatric care are demonstrated. But it means the trial tells you nothing about semaglutide used instead of treatment, which is exactly how a lot of people will be tempted to use it. The therapy was part of the package that worked.
The comorbid obesity question
The Lancet trial enrolled patients with alcohol use disorder and comorbid obesity. That was a sensible design choice — semaglutide is licensed for weight management, so it’s a population where prescribing is already plausible — but it constrains what the result generalises to.
We do not know from this trial whether semaglutide reduces heavy drinking in people with alcohol use disorder who are not obese. The 2025 trial provides some reassurance in that direction, since its participants weren’t selected for obesity and it used low doses, but 48 people is a thin basis.
It’s also a reasonable question whether some of the benefit runs through weight loss, general reward-system effects, or something specific to alcohol. The mechanism isn’t settled, and it doesn’t need to be for the finding to be useful — but it does mean caution about extrapolating.
What these trials don’t establish
- Long-term effect. The longer trial ran 26 weeks. Alcohol use disorder is a long-term condition; what happens at two years is unknown.
- What happens on stopping. No data here on whether benefits persist after the drug is discontinued.
- Generalisability beyond obesity, as above.
- Single-centre results. The Lancet trial was conducted at one centre; multi-centre replication is the standard next step.
- Safety in this specific population over time. Semaglutide’s side effect profile is well characterised in diabetes and obesity, but people with alcohol use disorder often have liver disease, nutritional deficiencies and other complications.
- Comparative effectiveness. No head-to-head trial against naltrexone or acamprosate.
It is not approved for this
These are research findings, not a licensed indication. Any use for this purpose would be off-label, which is a decision for a doctor who knows your full history — not something to arrange yourself.
Do not buy semaglutide online. The market for GLP-1 drugs outside proper prescribing has attracted compounded, counterfeit and mislabelled products, and injectables carry dosing and contamination risks that tablets don’t. If this interests you, the route is a conversation with a doctor about whether it’s appropriate — including whether a licensed treatment for alcohol use disorder would be a better first step.
The treatments that already exist
One reason this story got so much attention is that many people don’t know there are already licensed medications for alcohol use disorder — and they are substantially underused.
| Approach | Status | Note |
|---|---|---|
| Naltrexone | Licensed for AUD | Reduces heavy drinking; well established |
| Acamprosate | Licensed for AUD | Supports abstinence after withdrawal |
| Disulfiram | Licensed for AUD | Causes an unpleasant reaction to alcohol; needs supervision |
| Cognitive behavioural therapy | Standard care | Was given to both arms in the Lancet trial |
| Mutual support groups | Widely available | Free; effective for many people |
| Semaglutide | Not approved for AUD | Promising trial evidence; off-label only |
If you have a drinking problem, the licensed options are available now, from a GP, and don’t require waiting for a research pipeline. The most common reason people don’t use them is that nobody told them they exist.
The warning that matters most
Abrupt cessation of heavy, regular alcohol use can cause severe withdrawal — including seizures and delirium tremens — and can be fatal. This is genuinely different from stopping smoking or cutting sugar, and it is the single most important thing on this page.
If you drink heavily most days, especially if you have ever had withdrawal symptoms — shaking, sweating, nausea, anxiety or a racing heart in the morning, or needing a drink to steady yourself — speak to a doctor before you reduce or stop. Medically supervised withdrawal is straightforward, safe and widely available. Doing it alone is the dangerous option.
Seek emergency help immediately for confusion, hallucinations, seizures, severe agitation, a high fever or a rapid heartbeat during withdrawal.
How to raise this with a doctor
- Be straightforward about how much you drink. Doctors are not shocked, and an accurate number is what makes the advice useful.
- Ask about licensed options first — naltrexone, acamprosate, disulfiram — and why one might suit you.
- Ask about therapy alongside. The Lancet trial’s benefit was on top of CBT, and CBT helps on its own.
- Mention the trials if semaglutide interests you, and ask whether off-label use would be reasonable in your case — accepting that the answer may be no.
- Ask about safe reduction if you drink daily. Do not begin cutting down before that conversation.
- Ask for liver function tests and a nutritional review. Both matter and both are easy to arrange.
Thiamine and heavy drinking
One nutritional point is genuinely important and often missed by people trying to cut down on their own.
Heavy alcohol use depletes thiamine (vitamin B1) — through poor intake, impaired absorption and increased losses. Severe thiamine deficiency causes Wernicke’s encephalopathy, a neurological emergency that can lead to permanent memory damage if untreated. Thiamine supplementation is routine clinical practice in the care of people who drink heavily, for precisely this reason.
Thiamine (Vitamin B1)
Routinely given in clinical care of heavy drinkers — and often missed by people reducing on their own
This is not a treatment for alcohol use disorder and it will not reduce your drinking. It addresses a specific, well-recognised risk: heavy alcohol use depletes thiamine, and severe deficiency causes Wernicke’s encephalopathy — a neurological emergency that can cause lasting memory damage. Supplementation is standard practice in clinical settings for exactly this reason, and it’s the thing people trying to cut down alone most often don’t know about. Tell your doctor you’re taking it and ask whether the dose is right for you — clinical doses differ from general supplement doses, and if there’s any suspicion of deficiency this needs medical rather than self-management. Most importantly: this is not a substitute for medical care, and it does nothing to make unsupervised withdrawal safe.
- Not a treatment for alcohol use disorder
- Tell your doctor — clinical doses differ from supplement doses
- Does nothing to make unsupervised withdrawal safe
- Ask about a full nutritional review and liver function tests
- Seek urgent care for confusion, unsteadiness or eye movement problems
Frequently asked questions
Does Ozempic actually reduce drinking?
Two randomised trials say yes, with caveats. A 2025 JAMA Psychiatry trial of 48 non-treatment-seeking adults found low-dose semaglutide reduced craving, drinks per drinking day and heavy drinking days, and cut consumption in an objective laboratory task. A 2026 Lancet trial of 108 treatment-seeking patients with moderate-to-severe alcohol use disorder and obesity found semaglutide 2.4 mg weekly significantly reduced heavy drinking days over 26 weeks, with a reported number needed to treat of 4.3. Both are relatively small and the Lancet trial was single-centre.
Is it approved for alcohol use disorder?
No. Semaglutide is not approved to treat alcohol use disorder anywhere — these are research findings, not a licensed indication. Any use for this purpose would be off-label and is a decision for a doctor who knows your full history. Do not buy semaglutide online: the market outside proper prescribing has attracted compounded, counterfeit and mislabelled products, and injectables carry dosing and contamination risks. There are licensed medications for alcohol use disorder available now.
What does “number needed to treat 4.3” mean?
It means roughly one in every four to five people treated gets a benefit they wouldn’t have had on placebo — and lower numbers are better. The reported comparison is 4.3 against 7 or higher for medications already approved for alcohol use disorder. Two caveats: NNTs from different trials aren’t directly comparable because populations, benefit definitions and trial lengths differ; and this figure comes from 108 patients at a single centre, and effect sizes from small single trials often shrink when larger multi-centre trials follow.
Did the participants get anything else?
Yes, and this is the most-omitted detail in the coverage. In the Lancet trial both arms received standard cognitive behavioural therapy — semaglutide or placebo was added on top. So the finding is that semaglutide plus structured psychological treatment beat psychological treatment alone. It says nothing about semaglutide used instead of treatment, which is how many people will be tempted to use it. The therapy was part of the package that worked.
What treatments already exist for alcohol use disorder?
Three licensed medications — naltrexone, which reduces heavy drinking; acamprosate, which supports abstinence after withdrawal; and disulfiram, which causes an unpleasant reaction to alcohol and needs supervision. Alongside those: cognitive behavioural therapy, which was given to both arms of the Lancet trial and helps on its own, and mutual support groups, which are free and effective for many people. These are available now from a GP. The most common reason people don’t use them is simply not knowing they exist.
Can I just stop drinking on my own?
Not safely, if you drink heavily every day. Abrupt cessation of heavy, regular alcohol use can cause severe withdrawal including seizures and delirium tremens, and can be fatal. If you have ever had morning shaking, sweating, nausea, anxiety or a racing heart, or needed a drink to steady yourself, speak to a doctor before you reduce or stop. Medically supervised withdrawal is straightforward, safe and widely available — doing it alone is the dangerous option. Seek emergency help immediately for confusion, hallucinations, seizures, severe agitation, high fever or rapid heartbeat.
Your checklist
- Two randomised trials support the effect — 2025 (n=48) and 2026 (n=108)
- The Lancet trial hit its primary endpoint at 26 weeks
- NNT 4.3 vs 7+ for approved AUD medications — encouraging, not settled
- Note that both arms received CBT — the drug was an addition
- The Lancet population had comorbid obesity — generalisability unclear
- Semaglutide is not approved for alcohol use disorder
- Never buy it online — counterfeits and compounding risks are real
- Licensed options exist now: naltrexone, acamprosate, disulfiram
- CBT and support groups work and are available
- Do not stop heavy daily drinking suddenly — withdrawal can kill
- See a doctor before reducing if you drink daily
- Ask about thiamine, liver function tests and a nutritional review
- Get emergency help for confusion, seizures or hallucinations
Medical disclaimer. This article is general information and not medical advice. Do not obtain or use semaglutide for this or any purpose without a prescription from a doctor who knows your medical history, and do not buy it online. Most importantly: if you drink heavily every day, do not stop or sharply reduce without medical advice — alcohol withdrawal can cause seizures and delirium tremens and can be fatal. Medically supervised withdrawal is safe and widely available. Seek emergency help immediately for confusion, hallucinations, seizures, severe agitation, high fever or rapid heartbeat. If you are worried about your drinking, speak to your doctor — licensed medications and effective psychological treatments are available now.
Affiliate disclosure. Some links on this page are affiliate links. As an Amazon Associate we earn from qualifying purchases. The product mentioned addresses a nutritional risk associated with heavy drinking; it is not a treatment for alcohol use disorder and does not make unsupervised withdrawal safe.
